Endeavor II Four-Year Results Demonstrate Long-Term Safety And Durable Efficacy Of Medtronic Drug-Eluting Stent
May 15th, 2008 by 
admin Today at EuroPCR, Medtronic, Inc. (NYSE: MDT), free four-year accumulation from the ENDEAVOR II clinical effort that reinforces the long-term country and imperishable effectualness of the company’s Endeavor Zotarolimus-Eluting Coronary Stent System for the communication of thrombosis arteria disease. “As the continuance of follow-up in ENDEAVOR II grows, so likewise does our certainty in the lasting country and power of the Endeavor stent,” said Dr.
Posted in Cardiology | 